Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Prolonged sedation due to accumulation of conjugated metabolites of midazolam.

Bauer TM, Ritz R, Haberthür C, Ha HR, Hunkeler W, Sleight AJ, Scollo-Lavizzari G, Haefeli WE.

Lancet. 1995 Jul 15;346(8968):145-7.

PMID:
7603229
2.

Reversal of prolonged sedation using flumazenil in critically ill patients.

Bodenham A, Park GR.

Anaesthesia. 1989 Jul;44(7):603-5.

3.
4.

[The efficacy of the benzodiazepine antagonist flumazenil (Ro 15-1788) based on the EEG of mechanically ventilated intensive care patients].

Kulka PJ, Lauven PM, Schwilden H, Rommelsheim K.

Anaesthesist. 1989 Aug;38(8):424-30. German.

PMID:
2506776
5.

Attenuation of midazolam-induced EEG activation in rats by both flumazenil and hyperbaric oxygen.

Russell GB, Vance WT, Graybeal JM.

J Neurosurg Anesthesiol. 1995 Oct;7(4):271-9.

PMID:
8563448
6.

Pharmacology of Dormicum (midazolam) and Anexate (flumazenil).

Amrein R, Hetzel W.

Acta Anaesthesiol Scand Suppl. 1990;92:6-15; discussion 47. Review.

PMID:
2109472
7.

Benzodiazepine receptor equilibrium constants for flumazenil and midazolam determined in humans with the single photon emission computer tomography tracer [123I]iomazenil.

Videbaek C, Friberg L, Holm S, Wammen S, Foged C, Andersen JV, Dalgaard L, Lassen NA.

Eur J Pharmacol. 1993 Nov 2;249(1):43-51.

PMID:
8282018
9.

Pharmacology of saccadic eye movements in man. 1. Effects of the benzodiazepine receptor ligands midazolam and flumazenil.

Ball DM, Glue P, Wilson S, Nutt DJ.

Psychopharmacology (Berl). 1991;105(3):361-7.

PMID:
1665920
10.

Reversal of midazolam sedation with flumazenil.

Breheny FX.

Crit Care Med. 1992 Jun;20(6):736-9.

PMID:
1597024
11.

Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects.

Ebert U, Oertel R, Kirch W.

Clin Pharmacol Ther. 2000 May;67(5):538-48.

PMID:
10824633
12.

Extra-hepatic metabolism of midazolam.

Park GR, Manara AR, Dawling S.

Br J Clin Pharmacol. 1989 May;27(5):634-7.

13.

The use of midazolam and flumazenil in diagnostic and short surgical procedures.

Whitwam JG.

Acta Anaesthesiol Scand Suppl. 1990;92:16-20; discussion 47. Review.

PMID:
2109463
14.

Pharmacodynamic modeling of the electroencephalographic effects of flumazenil in healthy volunteers sedated with midazolam.

Fiset P, Lemmens HL, Egan TD, Shafer SL, Stanski DR.

Clin Pharmacol Ther. 1995 Nov;58(5):567-82. Erratum in: Clin Pharmacol Ther. 2003 Mar;73(3):271. Egan, TE [corrected to Egan, TD].

PMID:
7586951
15.

Reversal of sedation by prolonged infusion of flumazenil (Anexate, Ro 15-1788).

Bodenham A, Brownlie G, Dixon JS, Park GR.

Anaesthesia. 1988 May;43(5):376-8.

17.

Clinical pharmacokinetic monitoring of midazolam in critically ill patients.

Spina SP, Ensom MH.

Pharmacotherapy. 2007 Mar;27(3):389-98. Review.

PMID:
17316150
18.

Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients.

Boulieu R, Lehmann B, Salord F, Fisher C, Morlet D.

Eur J Drug Metab Pharmacokinet. 1998 Apr-Jun;23(2):255-8.

PMID:
9725490
19.

Flumazenil's reversal of myoclonic-like movements associated with midazolam in term newborns.

Zaw W, Knoppert DC, da Silva O.

Pharmacotherapy. 2001 May;21(5):642-6.

PMID:
11349753
20.

Effect of flumazenil on electroencephalographic patterns induced by midazolam.

Wojna V, Guerrero L, Guzmán J, Cotto M.

P R Health Sci J. 2000 Dec;19(4):353-6.

PMID:
11293887

Supplemental Content

Support Center